Upfront Pemigatinib for Chronic-Phase Myeloid/Lymphoid Neoplasm With a Novel FGFR1 Rearrangement Presenting as Transient Bilateral Vision Loss: A Case Report (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-875; Location: LEVEL 3, HALL B3; "This case highlights the importance of early recognition of MLN-FGFR1 in patients with unexplained eosinophilia and atypical neurologic symptoms. Early molecular diagnosis enabled prompt initiation of targeted therapy, resulting in rapid and profound hematologic and cytogenetic response. These findings support upfront pemigatinib as an effective bridge to allo-HSCT in chronic-phase MLN-FGFR1, including cases with rare ZNF198::FGFR1 fusions."
Case report • Clinical • Hematological Malignancies • Leukemia • Myeloproliferative Neoplasm • Oncology • FGFR1 • RUNX1 • ZMYM2
|
|
Jorge Sanchez-Orbe MD 1,2; Maria Felix Torres-Nolasco MD 1,2; Heloi Stefani MD 1,2; Jean Bustamante MD 1,2
|